A picture handled June 16, 2020 in Paris shows tablets of Dectancyl, a drug made by Sanofi containing dexamethasone. The steroid dexamethasone has been discovered to conserve the lives of one third of the most major COVID-19 cases, according to trial results hailed on June 16, 2020 as a ‘major development’ in the fight against the disease. Scientists led by a team from the University of Oxford administered the widely offered drug to more than 2,000 seriously ill COVID-19 patients. Amongst those who might only breathe with the aid of a ventilator, dexamethasone lowered deaths by 35 percent, and it reduced deaths of those receiving oxygen by a fifth, according to preliminary results.( AFP/Bertrand Guay )
Indonesian medical experts are considering adding dexamethasone to update the national COVID-19 treatment protocol following recent global trials on prospective prospect treatments for the illness.
Dexamethasone, an economical and widely readily available steroid, was recently hailed as a “significant breakthrough” in dealing with severe cases of COVID-19 The anti-inflammatory drug is commonly used to treat arthritis, allergic reactions, immune system conditions and breathing disorders.
” We [on the protocol panel] have actually been discussing dexamethasone the previous 3 days due to the fact that the results in England were quite persuading,” said pulmonologist Agus Dwi Susanto.
As the chair of the Indonesian Society of Respirology (PDPI), Agus was associated with drafting the country’s COVID-19 treatment protocol in addition to the Indonesian Cardiovascular Specialists Association (PERKI), t.
